Faldaprevir

Drug Profile

Faldaprevir

Alternative Names: BI-201335; BI-201335-NA; BI-201335-sodium; BI-201335Na; Faldaprevir-sodium

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Trek Therapeutics
  • Class Amides; Antivirals; Carboxylic acids; Cyclopropanes; Oligopeptides; Pyrrolidines; Quinolines; Small molecules; Thiazoles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 01 Sep 2017 Trek Therapeutics completes a phase II trial in Hepatitis C (Combination therapy, Treatment-naive) in New Zealand and USA (PO) (NCT02716428)
  • 14 Feb 2017 Efficacy and adverse events data from a phase IIa trial in Hepatitis C released by Trek Therapeutics
  • 19 Sep 2016 Efficacy and adverse events data from a phase IIa trial in Hepatitis C released by Trek Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top